Browse the evidence

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.

Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.

All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC), HDL-C, VLDL-C, triglyceride (TG), and waist circumference (WC) changes from baseline compared with control agents.

Tirzepatide may be considered as an effective treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

Only 5 mg once-weekly tirzepatide could induce significant alteration in LDL-C before sensitivity analysis.

Clinicians should note that the 5 mg dose of tirzepatide may be more effective for lowering LDL-C compared to higher doses.

Tirzepatide had superiority over placebo or other antidiabetic agents in controlling lipid and waist circumference levels.

Tirzepatide may be a preferred treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

GLP-1RA use in MUHO is associated with a lower risk of ischemic stroke (HR 0.921) compared to non-use.

GLP-1RAs may be beneficial for reducing ischemic stroke risk in MUHO patients.

Patients with metabolically healthy obesity (MHO) have a markedly lower risk of clinical events compared to those with metabolically unhealthy obesity (MUHO).

Understanding the risk differences can guide treatment decisions for obesity management.

Testosterone replacement therapy significantly decreased waist circumference from 88.6 ± 13.1 cm to 83.9 ± 12.9 cm (P < 0.01).

Practitioners can consider testosterone replacement therapy for reducing waist circumference in hypogonadal patients.

Testosterone replacement therapy resulted in a significant increase in lean body mass from 46,906 ± 8,876 gm to 50,083 ± 7,590 gm (P < 0.001).

Practitioners may use testosterone replacement therapy to enhance lean body mass in hypogonadal patients.

Semaglutide has a favorable safety profile across diverse patient populations and treatment durations.

Clinicians can consider semaglutide as a safe option for managing type 2 diabetes and obesity.

Females tended to lose more weight (Mean = 9.75) than males (Mean = 8.41).

Practitioners may consider gender differences when designing weight-loss interventions.

Diabetes management is being transformed by continuous glucose monitoring (CGM) systems and closed-loop insulin delivery.

Healthcare providers should adopt CGM systems and closed-loop delivery for improved diabetes management.

Effects on gastric emptying appeared additive when BI 1820237 was combined with low-dose liraglutide.

Combining BI 1820237 with liraglutide may enhance effects on gastric emptying, which could be relevant for treatment strategies.

The combination of long-acting PYY analogs with a GLP-1 receptor agonist resulted in superior blood glucose lowering and greater body weight loss compared to GLP-1 alone.

Suggests a potential strategy for enhanced diabetes and obesity treatment.

Co-agonism of the glucagon and GLP-1 receptors improves glycemia in people with diabetes and obesity.

Practitioners may consider glucagon and GLP-1 receptor co-agonists as a treatment option for improving glycemia.

Continuous glucose monitoring can provide benefits when initiating GLP-1RA treatment.

Implementing continuous glucose monitoring can enhance the safety and effectiveness of GLP-1RA therapy.

The gut is a promising target for therapeutic interventions to achieve significant weight loss.

Practitioners should consider gut-targeted therapies as viable options for obesity treatment.

The quality of life after ESG was rated as good or better by 82% of patients.

Practitioners can expect significant improvements in patient quality of life following ESG.

GLP-1 receptor agonists have better side-effect profiles than other weight management treatments.

Healthcare providers may prefer GLP-1 receptor agonists for patients due to their favorable side-effect profiles.

An oral formulation of semaglutide (7 or 14 mg once daily) has been approved by the FDA for the treatment of type 2 diabetes.

Practitioners can consider the oral formulation of semaglutide as an option for managing type 2 diabetes.

Dual and triple agonists show effectiveness on validated surrogate NAFLD biomarkers.

There is potential for dual and triple agonists to be effective in treating NAFLD, warranting further investigation.

GIP receptor agonism and antagonism both lead to weight reduction.

Both GIP receptor agonists and antagonists could be explored for obesity treatment strategies.

The macrovascular benefits of GLP-1 receptor agonists should be prioritized over potential microvascular progression of DR.

Healthcare providers should weigh the cardiovascular benefits of GLP-1 receptor agonists against the risks of worsening DR.